

1 **Investigating antibody reactivity to the intestinal microbiome in severe**
2 **myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)**

3

4 Katharine A. Seton¹, Marianne Defernez¹, Andrea Telatin¹, Sumeet K. Tiwari¹,
5 George M. Savva¹, Antonietta Hayhoe¹, Alistair Noble³, Ana Carvalho⁴, Steve
6 James¹, Amolak Bansal⁵, Thomas Wileman^{1,2} and Simon R. Carding^{1,2}

7

8 ¹*Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK*

9 ²*Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK*

10 ³*The Pirbright Institute, Woking, GU24 0NF, UK*

11 ⁴*Experimental Arthritis Treatment Centre for Children, University of Liverpool, Liverpool,*
12 *L12 2AP*

13 ⁵*Spire St Anthony's Hospital, Surrey, SM3 9DW, UK*

14

15

16 Corresponding author:

17 Prof. Simon R. Carding

18 Food, Microbiome and Health Research Programme

19 Quadram Institute Bioscience

20 Norwich Research Park

21 Norwich, NR4 7UQ

22 U.K.

23 (e) simon.carding@quadram.ac.uk

24 **Abstract**

25 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease of
26 unknown aetiology that is characterised by disabling chronic fatigue and involves both the
27 immune and gastrointestinal (GI) systems. Patients display alterations in GI microbiome with
28 a significant proportion experiencing GI discomfort and pain and elevated blood biomarkers
29 for altered intestinal permeability compared with healthy individuals. To investigate a
30 possible GI origin of ME/CFS we designed a feasibility study to test the hypothesis that
31 ME/CFS pathogenesis is a consequence of increased intestinal permeability that results in
32 microbial translocation and a breakdown in immune tolerance leading to generation of
33 antibodies reactive to indigenous intestinal microbes. Secretory IgA and serum IgG levels
34 and reactivity to intestinal microbes were assessed in five pairs of severe ME/CFS patients
35 and matched same-household healthy controls. For profiling serum IgG we developed IgG-
36 Seq which combines flow-cytometry based bacterial cell sorting and metagenomics to detect
37 mucosal IgG reactivity to the microbiome. We uncovered evidence for immune dysfunction
38 in severe ME/CFS patients that was characterised by reduced capacity and reactivity of serum
39 IgG to stool microbes, irrespective of their source. This study provides the rationale for
40 additional studies in larger cohorts of ME/CFS patients to further explore immune-
41 microbiome interactions.

42

43 **Keywords:** Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), antibodies,
44 immunoglobulin G, immunoglobulin A, microbiome, autologous, heterologous, immune tolerance,
45 leaky gut.

46 **Introduction:**

47 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterised by disabling
48 fatigue and autonomic, muscular, cognitive, neurological and immune symptoms that leave
49 patients unable to undertake their pre-morbid work, education, exercise and social activities¹.
50 A quarter of diagnosed patients are house- or bedbound² and less than 5% ever recover their
51 pre-morbid activity levels³. A meta-analysis based on 45 studies estimated an average
52 population prevalence of 0.68% (95%CI = 0.48 to 0.97)⁴. However, these estimates vary
53 considerably by population and case definition⁴. The prevalence is anticipated to rise
54 following the COVID-19 pandemic as 45.2% of long COVID patients fulfil ME/CFS
55 diagnostic criteria⁵. The most common trigger of ME/CFS is an infection, while other
56 reported triggers include physical or mental trauma and toxin exposure³.

57 Several factors have been implicated in ME/CFS pathogenesis involving the immune
58 (autoimmunity, inflammation and chronic infection), gastrointestinal (GI), neurological,
59 endocrine and metabolic systems⁶. Between 38 and 92% of ME/CFS patients report co-
60 morbid GI disturbances such as IBS^{3,7-9} and 35% of patients take medication for GI
61 disturbances including pro- and prebiotics, digestive enzymes and sodium bicarbonate³. The
62 high co-occurrence of ME/CFS and IBS suggests possible involvement of the intestinal
63 microbiome. Consistent with this possibility several studies have reported changes in the
64 community structure of the stool microbiome of ME/CFS patients exemplified by reduced
65 diversity⁸ and decreased abundance of short-chain fatty acid producing bacterial species⁸⁻¹².
66 ME/CFS patients may also have elevated biomarkers associated with increased intestinal
67 permeability^{8,13,14}. Intestinal inflammation and increased permeability can compromise
68 immune and microbial tolerance (defined as a state of hypo responsiveness to autologous
69 intestinal microbes)¹⁵ leading to hyperreactivity and serum antibody production to
70 autologous intestinal microbes¹⁶; this can pre-stage autoimmune disease¹⁷. Of note, ME/CFS

71 patients displaying increased intestinal permeability have a higher incidence of serotonin
72 autoimmunity¹⁸.

73 Based upon these observations we hypothesised that ME/CFS pathology is a
74 consequence of the breakdown in immune tolerance resulting from the increased intestinal
75 permeability and microbial translocation that leads to generation of antibodies reactive to
76 autologous intestinal microbes. In support of this proposal, a previous study found that,
77 compared with healthy controls, ME/CFS patients had abnormally high levels of IgA and
78 IgM produced in response to a panel of seven gram-negative enterobacteria¹³. However, this
79 small panel of microbes does not reflect the complexity of the intestinal microbiota which
80 comprises 300-500 bacterial species as well as viruses, archaea and fungi¹⁹. In addition, IgM
81 antibodies have low specificity for antigens²⁰ and IgA is primarily produced at mucosal
82 sites²¹. Serum IgG reactivity to the microbiome in ME/CFS patients has recently been
83 investigated using phage immunoprecipitation sequencing (PhIP-Seq) to screen IgG
84 reactivity to 244,000 bacterial and viral epitopes²². This study is, however, restricted to
85 identifying antibody reactivity to peptide antigens and cannot detect reactivity to the
86 immunogenic glycoproteins and lipoproteins that decorate the outer membrane and surface of
87 bacterial cells, viruses and fungi²³. Furthermore, none of the approaches used to date provide
88 information on whether immune tolerance to indigenous intestinal microbes is lost in
89 ME/CFS.

90 To begin to address this important question and assess the systemic humoral immune
91 response to indigenous microbes we adapted ‘IgA-Seq’, a method that combines flow-
92 cytometry-based bacterial cell sorting and 16S rRNA sequencing to detect mucosal IgA
93 reactivity to the microbiome²⁴, to characterise serum IgG reactivity to the microbiome; we
94 refer to this new method as IgG-Seq. To evaluate the IgG-Seq protocol, we designed a
95 feasibility study with a small cohort of severe ME/CFS patients and healthy controls from the

96 same households. The difficulty in accessing housebound or bedbound patients is a major
97 obstacle to understanding the pathophysiology and aetiology of ME/CFS and is why only
98 0.5% of ME/CFS research is undertaken in severely affected patients². One aim of this study,
99 therefore, was to assess the feasibility of, and barriers to, including severe ME/CFS patients
100 in research involving the collection of biological samples.

101

102 **Results:**

103 *Recruiting severe ME/CFS patients and same household controls*

104 Study participants were recruited from the CFS clinic at Epsom and St Helier University
105 Hospitals (ESTH), Carshalton, UK and the ME/CFS service at East Coast Community
106 Healthcare Centre, Lowestoft, UK which together had 3,812 registered patients. Recruitment
107 began in October 2017, with the intention of recruiting ten severe house- or bedbound
108 ME/CFS patients and ceased in April 2020 due to the COVID-19 pandemic. Thirty-six
109 patients were invited to the study with a response rate of 58.3% (Supplementary Fig. S1). Of
110 those who responded, 42.9% were ineligible due to either the absence of a household control
111 (n = 4), failure to meet other inclusion criteria (n = 4) or were unable to provide written
112 informed consent (n = 1). Of the 12 eligible pairs of participants, six provided informed
113 consent. The consenting appointments for the other six eligible participants were delayed
114 either due to patients rescheduling their appointments when feeling unwell, or the non-
115 availability of phlebotomists to attend home visits. Consequently, consenting appointments
116 were delayed by up to 12 months for participants, by which point three patients either saw
117 their health further deteriorate preventing them from participating in the study, or acquired an
118 additional health complication that excluded them from the study. We received no further
119 communication from the remaining three pairs.

120 ***Study population characteristics***

121 Samples were collected from five pairs of participants; one pair consented immediately prior
122 to the COVID-19 pandemic which prevented us from obtaining their samples (Table 1). The
123 recruited patients comprised four females and one male (mean age 33.8 years; standard
124 deviation (SD) 13.8). There was clinical heterogeneity amongst patients, with variation in the
125 age at which ME/CFS onset occurred, length of illness and symptom severity. Three patients
126 reported ME/CFS onset following a viral infection, one following vaccination and one
127 following surgery. IBS was reported in all patients but in none of their matched household
128 controls. Same household healthy controls included four males and one female (mean age
129 40.4 years; SD 16.7) who were the carers and spouse (n = 3), parent (n = 1) or sibling (n = 1)
130 of the patients.

131 ***Stool consistency does not separate severe ME/CFS patients with IBS from matched***
132 ***household controls without IBS***

133 Despite all ME/CFS patients, and no household controls, reporting IBS there was no evidence
134 for a difference in consistency of the collected stool samples between patients and controls,
135 as measured by the Bristol stool form scale (BSFS) or by water content (Fig. 1A and 1B).
136 Three controls had abnormally loose stools (BSFS 5-7) indicative of diarrhoea and one
137 control had an abnormally hard stool (BSFS 2) indicative of constipation. In contrast, two
138 patients had stool samples defined as having a healthy consistency (BSFS 3-4), one patient
139 had an abnormally loose stool (BSFS 5) and two patients had abnormally hard stools (BSFS
140 1-2).

141 ***Assessment of secretory IgA in stool***

142 The concentrations of microbe bound IgA1/2 (Fig. 2A) and free IgA1/2 (Fig. 2B) were
143 measured by ELISA with no evidence of a significant difference between severe ME/CFS

144 patients and their matched household controls. Flow cytometry was used to determine the
145 distribution of IgA coating on stool microbes (Fig. 3A and 3B). When comparing the
146 proportion of stool microbes coated by IgA there was no evidence of any differences between
147 patients and matched controls (Fig. 3C). Based on the microbial load of stool samples
148 (Supplementary Fig. S2) the relative quantification of IgA bound microbes was converted to
149 absolute values which again revealed no evidence of differences between patients and
150 matched controls in the quantity of IgA coated microbes within stool samples (Fig. 3D).

151 *Severe ME/CFS patients have a reduced serum IgG immune response to stool microbes*

152 To determine whether immune tolerance to intestinal microbes was altered in severe ME/CFS
153 patients the level of serum IgG antibodies bound to both their own (autologous) stool
154 microbes and to non-self (heterologous) stool microbes from other individuals were measured
155 in patients and their matched household controls (Fig. 4A). Four patients had lower serum
156 IgG reactivity to indigenous stool microbes than their matched household controls ($p =$
157 0.07322) and all patients had lower serum IgG reactivity to foreign stool microbes than their
158 matched household controls ($p = 0.006334$) (Fig. 4B). Furthermore, there was evidence for
159 controls having higher serum IgG reactivity to heterologous (patient) stool microbes than
160 serum IgG reactivity to autologous stool microbes ($p = 0.0317$). In contrast, for patients there
161 was no evidence for a difference in serum IgG reactivity to autologous and heterologous
162 (control) stool microbes ($p = 0.3619$). In addition, serum IgG reactivity to patients
163 (heterologous) stool microbes in control individuals was higher than serum IgG reactivity to
164 autologous stool microbes in patients ($p = 0.003751$). A paired t-test of the averaged IgG
165 levels to indigenous and foreign stool microbes within individuals suggests that patients had a
166 lower IgG reactivity to stool microbes than controls irrespective of the source of the microbes
167 ($p = 0.0185$). Of note, the reduced levels of patient IgG antibodies to indigenous and foreign
168 stool microbes were not due to lower levels of serum IgG in patients (Fig. 4C).

169 ***The proportion of microbes bound by serum IgG is high in both patients and controls***

170 We next sought to determine how much of the stool microbiome was recognised by serum
171 IgG by measuring the proportion of indigenous stool microbes coated by serum IgG (Fig. 5A
172 and 6B). There was no evidence for any differences in the proportion of stool microbes
173 coated by IgG ('IgG positive') in severe ME/CFS patients compared with controls (Fig. 5C).

174 ***Characterising the stool microbiome***

175 Using whole metagenome shotgun sequencing the microbial composition of SYBR Green⁺
176 ('all') stool microbes isolated by fluorescent activated cell sorting (FACS) was determined
177 (Supplementary Fig. S3). The average number of 'all' microbes collected by FACS was 1.47
178 million. Taxa with a relative abundance greater than 1×10^{-6} were included in downstream
179 analyses and comparisons made at the genus and species level.

180 At the genus level 275 taxa were detected. The 15 most abundant genera across all
181 ME/CFS and matched household control samples (n = 10) were *Bacteroides* (10.4%),
182 *Phocaeicola* (10.1%), *Clostridioides* (9.5%), *Lysobacter* (9.4%), *Faecalibacterium* (8.6%),
183 *Blautia* (7.1%), *Roseburia* (5.8%), *Anaerostipes* (5.5%), *Akkermansia* (4.4%),
184 *Campylobacter* (2.9%), *Agrobacterium* (2.6%), *Methanobrevibacter* (1.9%), *Bifidobacterium*
185 (1.9%) *Anaerobutyricum* (1.5%) and *Streptococcus* (1.3%) (Supplementary Fig. S3A).

186 At the species level 705 taxa were detected. The 15 most abundant species across all
187 ME/CFS and matched household control samples (n = 10) were *Clostridioides difficile*
188 (9.5%), *Lysobacter enzymogenes* (9.4%), *Faecalibacterium prausnitzii* (8.6%), *Phocaeicola*
189 *dorei* (6.4%), *Blautia* sp. SC05B48 (6.3%), *Anaerostipes hadrus* (5.4%), *Roseburia*
190 *intestinalis* (4.5%), *Akkermansia muciniphila* (4.3%), *Bacteroides uniformis* (3.7%),
191 *Phocaeicola vulgatus* (3.6%), *Agrobacterium tumefaciens* (2.5%), *Methanobrevibacter*

192 *smithii* (1.8%), *Bacteroides cellulosilyticus* (1.6%), *Anaerobutyricum hallii* (1.5%) and
193 *Campylobacter jejuni* (1.5%) (Supplementary Fig. S3C).

194 Using three measures of intra-sample diversity, the Shannon index, inverse Simpson
195 index and observed richness, there was no evidence for differences in any of the alpha
196 diversity measures between severe ME/CFS patients and matched household controls at the
197 species level (Supplementary Fig. 4A).

198 Due to the large variation in microbial load in stool samples from severe ME/CFS
199 patients (6.3×10^{10} cells/gram to 2.6×10^{11} cells/gram) and controls (1.2×10^{11} cells/gram to
200 2.0×10^{11} cells/gram) (Supplementary Fig. S2), converting relative abundances to absolute
201 abundances increased the heterogeneity amongst samples at both the genus and species levels
202 (Supplementary Fig. S3B and S2D). However, analysis of beta diversity using Bray-Curtis
203 dissimilarity identified subtle changes in both relative microbiome profiles (RMP) and
204 quantitative microbiome profiles (QMP). Samples from patients in pairs three, four and five
205 were most dissimilar to the other samples while samples from patients in pairs one and two
206 clustering together with their matched household controls (Supplementary Fig. S4B).

207 Functional differences in the microbiome of patients and controls were determined by
208 comparing the abundance of gene families in the ‘all’ fraction. A total of 464,263 gene
209 families were detected in all participants above the threshold. A further filtering step removed
210 gene families below the threshold in more than seven samples, leaving 84,888 gene families
211 for evaluation. PCA was used to reduce the number of variables by defining principal
212 components (PC) that highlighted the largest sources of variation amongst the samples. PC4
213 identified 11% of variation in functional genes families amongst samples that were
214 attributable to disease status (Supplementary Fig. S5).

215 ***IgG-Seq identifies antimicrobial signatures unique to each participant***

216 Next, IgG-Seq was used to characterise the indigenous gut microbes bound by serum IgG in
217 severe ME/CFS patients and matched household controls. Briefly, ‘IgG positive’ and ‘IgG
218 negative’ microbes were isolated by FACS from bulk stool samples and processed for
219 shotgun metagenomic sequencing to identify taxa preferentially bound by serum IgG (Fig.
220 6A and 6B). The mean number of ‘IgG positive’ microbes collected by FACS was 1.05×10^6 .
221 The mean number of ‘IgG negative’ microbes isolated by FACS was 1.30×10^6 . Taxa with a
222 relative abundance greater than 1×10^{-5} in the ‘all’ fraction were included in the ‘IgG
223 positive’ and ‘IgG negative’ fractions for downstream analyses. Taxonomic comparisons
224 were made at the species level.

225 Observed richness scores were applied to rarefied reads to determine the number of
226 microbial species with serum IgG reactivity (Fig. 6C). All participants had more than 200
227 species in the ‘IgG positive’ fraction with a high number of species also identified in the ‘IgG
228 negative’ fraction. Both patients and controls had a higher mean number of species in their
229 ‘IgG negative’ fraction than their ‘IgG positive’ fraction (365 vs 339 in patients and 358 vs
230 322 in controls). However, most participants had a small number of species (<30) exclusively
231 in the ‘IgG negative’ fraction at a relative abundance $>1 \times 10^{-5}$, except for the patient from
232 pair three who had 107 species exclusively in their ‘IgG negative’ fraction (Table 2). In
233 addition, this patient also had a smaller proportion of species recognised by IgG compared
234 with all other participants (Table 2).

235 Next, we assessed the similarity/difference between ‘IgG positive’ and ‘IgG negative’
236 fractions in patients and controls using the Bray-Curtis index and visualising distances using
237 an NMDS plot (Fig. 6D). ‘IgG positive’ and ‘IgG negative’ fractions from the same
238 participant shared the greatest similarity. No clustering was seen for either fraction in patients
239 or controls. The ‘IgG positive’ and ‘IgG negative’ fractions from patients in pairs three and
240 five were most dissimilar to the other samples.

241 Using the probability ratio developed by Jackson et al., (2021)²⁵ we scored IgG
242 binding by directly measuring the likelihood of a species being bound by IgG. Positive IgG
243 probability ratios indicate that a species is more likely to be coated with IgG and reside in the
244 ‘IgG positive’ fraction. Conversely, negative IgG probability ratios indicate that a species is
245 more likely to be uncoated and reside in the ‘IgG negative’ fraction. Probability ratios are not
246 influenced by the relative abundance of a species within the ‘all’ fraction and therefore
247 measure the quantity of IgG produced against a given species. Of the 423 species detected at
248 a relative abundance greater than 10^{-5} , 101 species were detected in every participant and
249 therefore used in downstream analysis. It is worth noting that despite detecting species falling
250 into the bacteria, fungi, archaea and virus kingdoms, only bacterial species were detected in
251 every participant and consequently used in downstream analysis. Notably, owing to the way
252 in which probability ratios are calculated they tend to be similar across species within
253 participants, with some having consistently lower estimates across all species than others,
254 driven by their overall IgG probability ratio. Probability ratio scores varied amongst species
255 and participants. Each participant had a unique combination of probability ratio scores for
256 different species (Fig. 7). We were unable to meaningfully test for differences in probability
257 ratio scores between patients and controls for individual species due to the small sample size
258 and lack of power to detect significant changes.

259 Finally, we analysed the function of the microbial communities within the ‘IgG
260 positive’ and ‘IgG negative’ fractions by analysing the likelihood of a gene family being
261 present in a microbe bound by IgG. IgG probability ratios were calculated for the 1724 gene
262 families that were detected in all participants above the threshold. Using a PCA plot to assess
263 how the ten samples varied with regards to the likelihood of certain gene families being
264 present in microbes bound by IgG (Supplementary Fig. S6), a separation between severe

265 ME/CFS patients and controls from four households was observed (PC2), corresponding to
266 13% of explained variance.

267

268 **Discussion:**

269 This feasibility study highlights the logistical challenges of including severe, house- or
270 bedbound ME/CFS patients in research studies and collecting biological samples. Contrary to
271 our initial hypothesis, our findings from a small cohort of patients and controls suggests that
272 severe ME/CFS patients may have a reduced serum IgG immune response to stool microbes.

273 *Lessons learnt for the inclusion of severe ME/CFS patients in biomedical research*

274 Despite their significant disability severe ME/CFS patients were enthusiastic and eager to
275 participate in our study with a 58% response rate. However, severe ME/CFS often coincided
276 with additional illness complications that excluded these individuals from the study,
277 hindering recruitment. We also found that symptom severity of house- or bedbound ME/CFS
278 patients fluctuated, making it difficult to arrange home study visits. The wide geographical
279 distribution of participants' homes (30 – 140 miles from the research institute) restricted
280 sample collection with a minimum of two hours required for sample collection and
281 transportation to the laboratory.

282 We recruited controls from the same household as the patient to account for
283 environmental confounders of microbiome analyses such as living conditions and diet^{26,27}.
284 Previous studies have shown that inclusion of same household controls enables identification
285 of ME/CFS disease-specific microbiome changes²⁸. However, the requirement for a matched
286 healthy household control impacted on patient recruitment. Amongst patients not meeting the
287 study eligibility criteria, 44% were excluded due to being unable to identify a matched
288 household control. Considering that household controls were typically carers and parents or

289 spouses of the patient, it was not possible to match age and gender of patients and controls,
290 both of which are confounding variables for immunological^{29,30} and microbiome studies³¹.
291 Other confounders potentially discordant amongst patients and controls were BMI, exercise
292 and medications. Our finding of a sparse clustering between results from severe ME/CFS
293 patients and matched household controls suggests that these and perhaps other confounding
294 variables had an influence on immune response to the intestinal microbiome. Future studies
295 should consider including and accounting for as many of these confounding variables in
296 analysis as possible.

297 ***Severe ME/CFS patients have serum IgG hyporeactivity to stool microbes***

298 The hypothesis guiding our study was that ME/CFS patients have increased intestinal
299 permeability due to an altered microbiome, which results in translocation of intestinal
300 microbes into the circulation, triggering an immune response. Despite the low study sample
301 size, we found evidence that severe ME/CFS patients in fact have lower serum IgG levels
302 reactive to stool microbes than their matched household controls. This appears to be a
303 property of the patients' immune responses, rather than their microbiome which structurally
304 and functionally closely resembled that of their matched controls. Our findings mirror the
305 findings from pioneering studies investigating immune reactivity to faecal microbes in IBD
306 patients which demonstrated that healthy controls have higher serum IgG reactive to
307 heterologous stool microbes than to autologous stool microbes¹⁵. In our study heterologous
308 reactivity was measured using samples from individuals living in the same household which
309 are known to display greater similarity to patients' microbiomes than individuals living in
310 different households³². This should increase confidence in identifying microbes that
311 distinguish the microbiome of patients from controls as being a property of the disease.
312 Despite this advantage there were no differences in alpha diversity measures between severe
313 ME/CFS patients and matched household controls at the genus or species level. Instead, our

314 findings provide initial evidence for immune dysfunction in ME patients manifesting as a
315 reduced capacity and reactivity of serum IgG to stool microbes irrespective of their source.
316 Previous studies have described IgG immunodeficiencies in ME³³ which could explain why
317 we found reduced levels of serum IgG binding to stool microbes in severe ME/CFS patients.
318 However, there was no evidence of IgG immunodeficiencies in our severe ME/CFS patient
319 cohort. Instead, it may be attributable to IgG antibody repertoires and a less diverse repertoire
320 of antibodies directed at intestinal microbes. The loss of antibody diversity occurs naturally
321 during ageing and is a defining feature of immune senescence and declining immune function
322 in later life³⁴. The possibility of premature or accelerated immunosenescence should be a
323 focus of future studies, particularly as it relates to effector immune cells whose functionality
324 is compromised in ME patients, as previously described for NK cells³⁵, and here for B cells.
325 An additional possibility relates to immune hibernation in ME/CFS patients which produces a
326 hypometabolic state³⁶ that may limit lymphocyte responsiveness to foreign antigens and
327 increased tolerance to bacterial endotoxins³⁷.

328 *Limitations of the study in addressing the study hypothesis*

329 The severe ME/CFS patients recruited to this pilot study had comorbid IBS, whereas
330 household controls were free of any GI complaints. IBS comorbidity is a confounding
331 variable in ME/CFS microbiome studies as defined microbiome profiles have been described
332 that discriminate between patients with and without IBS comorbidity⁹. To establish whether
333 the results found in this pilot study of severe ME patients are disease specific future studies
334 should compare severe ME/CFS patients with and without comorbid IBS and compare severe
335 ME/CFS patients with comorbid IBS to IBS patients.

336 We were unable to confirm the presence of increased intestinal permeability within
337 the severe ME/CFS patient cohort. Based upon previous studies most ME patients (~67%)

338 will have increased intestinal permeability compared with healthy controls¹³. An intact
339 intestinal barrier in the severe ME/CFS patients recruited to this study might explain why
340 they did not have increased IgG reactivity to autologous stool bacteria compared with their
341 matched healthy household controls. It has been shown that levels of IgG reactive to
342 autologous stool bacteria are elevated in other diseases associated with increased intestinal
343 permeability such as Crohn's disease¹⁶. Future studies should seek to establish the integrity of
344 the intestinal barrier in severe ME/CFS patients.

345 The IgG-Seq protocol used in this research identified serum IgG produced in response
346 to bacteria and fungi. Whilst excluding reactivity to other constituents of the intestinal
347 microbiome in the current study, the method can be adapted to detect IgG reactivity to viruses
348 and archaea that can then be identified and isolated using FACS.

349 ***Conclusion***

350 Severe ME patients have historically been excluded from research studies. This pilot study
351 demonstrates the feasibility and challenges associated with including this important and
352 growing population of ME patients in research. In providing evidence of immune dysfunction
353 in severe ME/CFS patients, expressed as hyporesponsive serum IgG responses to intestinal
354 microbes, this study also provides the theoretical and methodological basis and rationale for
355 undertaking more detailed immune function studies in larger cohorts of ME patients.

356

357 **Patients and Methods**

358 ***Participant recruitment***

359 Ten volunteers were enrolled onto this study between 2018 and 2019: Five severe ME/CFS
360 patients and, as controls, five healthy individuals that were the patients' carers and living in

361 the same household. Severe ME/CFS participants were recruited by the tertiary referral
362 centres Epsom and St Helier University Hospitals (ESTH) CFS Service, Carshalton, UK, and
363 the East Coast Community Healthcare Centre (ECCHC) ME/CFS service, Lowestoft, UK.
364 All severe ME/CFS patients had a confirmed diagnosis of ME/CFS based on a hybrid of the
365 NICE 2007 guidelines³⁸ and the CDC-1994 criteria³⁹ and defined as experiencing at least four
366 of the following symptoms for a minimum of 4 months; cognitive difficulties, muscle pain,
367 multi-joint pain, new headaches, recurrent sore throats, cervical/axillary lymphadenopathy,
368 unrefreshing sleep and post exertional malaise. Severity was based on being unable to
369 undertake activities associated with daily living, wheelchair dependency for mobility and
370 being house- or bedbound and requiring aid for washing, using the toilet and eating. All
371 patients were asked to complete the Chalder fatigue questionnaire, shortened medical
372 outcomes study 36-item short form health survey (SF-36), hospital anxiety and depression
373 scale (HADS), a self-efficacy questionnaire, visual analogue pain rating scale and the
374 Epworth sleepiness scale. Matched household controls were defined as individuals who were
375 living with or caring for the severe ME/CFS patient. Matched household controls were
376 excluded if they had a long-term medical condition, in particular gastrointestinal conditions,
377 autoimmune diseases, anxiety, or depression; or were receiving immunomodulatory drugs,
378 statins, beta blockers or steroids. Participants consuming antibiotics or probiotic capsules
379 within the 6 weeks prior to sample collection were excluded.

380 The study was performed in accordance with the Declaration of Helsinki and the
381 International Conference on Harmonisation Good Clinical Practice (ICH GCP) Guideline,
382 and in compliance with national law. The research was approved by the NHS Health
383 Research Authority London Hampstead Research Ethics Committee (REC 17/LO/1102,
384 IRAS ID 218545). This study was registered on the clinicaltrials.gov database
385 (NCT03254823). All participants provided fully informed written consent. The collection,

386 storage and use of human tissue samples was carried out within the terms of the Human
387 Tissue Act 2004 (Human Tissue Authority).

388 *Sample collection and processing*

389 Fresh stool and blood samples were collected from each participant within a 24 h window
390 during a home visit. Twenty millilitres of blood were collected in serum separator tubes (BD
391 Vacutainer). Serum was separated from whole blood following the manufacturers protocol
392 and immediately stored at -80°C. Stool samples were collected immediately after defecation
393 in a Fecotainer® (AT Medical BV) with an Oxoid™ AnaeroGen™ compact sachet (Thermo
394 Scientific) to preserve anaerobic bacteria. The consistency and appearance of fresh stool
395 samples was recorded using the Bristol stool form scale (BSFS)⁴⁰. Stool samples were stored
396 at 4°C for <24 h. Following homogenisation aliquots of the bulk homogenate and of 40%
397 stool microbial glycerol suspensions were stored at -80°C. Glycerol stocks were prepared by
398 diluting stool samples (10% w/v) with PBS, collecting the supernatant following
399 centrifugation at 300g for 5 min at 20°C and diluted 1:1 with 80% v/v glycerol.

400 *Stool water content*

401 Non-diluted aliquots of stool were weighed before and after freeze drying using the
402 ModulyoD freeze dryer (Thermo Electron Corp.) for 12 h. Water content was calculated
403 using the following equation.

$$\frac{(\text{wet weight} - \text{dry weight})}{\text{wet weight}} \times 100$$

404 *Stool microbial load*

405 Non-diluted stool aliquots were thawed on ice and diluted (1% w/v) with PBS solution
406 containing 0.1% w/v BSA fraction V. Samples were homogenised using a Kimble™
407 Kontes™ Pellet Pestle™ Cordless motor and filtered through a 70 µm cell strainer. Filtered

408 microbial suspensions were diluted 1:1600, 1:3200 and 1:6400; then 200µl of each dilution
409 were incubated with 10µl of 1:100 SYBR™ Green I nucleic acid gel stain (Thermofischer
410 Scientific) for 30 min. Microbial load was determined using the Guava® easyCyte™ 5HT
411 equipped with a 488 nm laser. Prior to sample acquisition the instrument was cleaned
412 following manufacturers' instructions and calibrated using the Guava® easyCheck™ kit.
413 Stool microbes (SYBR Green+ events) were enumerated using Guava® Suite Software v3.3.

414 *Stool IgA concentration*

415 Non-diluted stool aliquots were thawed on ice, diluted (10% w/v) with 0.2M NaHCO₃, pH
416 9.4 and homogenised using a Kimble™ Kontes™ Pellet Pestle™ Cordless motor. Samples
417 were centrifuged twice at 16,000g for 5 min at 20°C and after both rounds of centrifugation
418 the pellet and supernatant were separated. The supernatants were pooled and used to analyse
419 free secretory IgA (sIgA) by ELISA. The pellet was washed and resuspended to the original
420 volume and used to analyse microbe associated/bound sIgA by ELISA. All reactants except
421 for the blocking solution and wash buffers were added in volumes of 100 µl/well. All washes
422 were repeated three times with PBS and 0.05% Tween™ 20 unless otherwise stated. Nunc
423 MaxiSorp™ flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4°C with
424 10-fold serial dilutions (1 to 1:1000000) of samples and with 2-fold serial dilutions (250-3.9
425 ng/ml) of a human colostrum IgA standard (Sigma), diluted with 0.2M NaHCO₃, pH 9.4.
426 Samples and standards were plated in duplicate. Plates were washed and then blocked for 3h
427 with 300µl/well of PBS, 0.05% Tween™ 20, 2% BSA fraction V, 1% normal mouse serum
428 (Thermo Fisher Scientific). Plates were washed and then incubated with 1000 ng/ml biotin
429 conjugated mouse anti-human IgA1/IgA2 monoclonal antibody (Pharmingen) diluted in PBS,
430 0.05% Tween™ 20, 2% BSA fraction V, 1% normal mouse serum. After 1h of incubation at
431 20°C plates were washed and incubated with 1:80000 HRP-Conjugated Streptavidin (Thermo
432 Fisher Scientific) diluted in PBS, 0.05% Tween™ 20, 2% BSA fraction V, 1% normal mouse

433 serum for 30 min at 20°C. Plates were washed six times and incubated with TMB high
434 sensitivity substrate solution (BioLegend® UK Ltd) for 5 min. The addition of 2N H₂SO₄
435 stopped the reaction and absorbances were read at 450 nm. IgA sample values were
436 determined by reference to standard curves.

437 *Serum IgG quantification*

438 Total serum IgG was measured using the commercial Invitrogen ELISA kit (Thermo Fisher
439 Scientific). Samples were measured in duplicate.

440 *Serum IgG levels to autologous and heterologous stool microbes*

441 Glycerol stocks of stool microbes were thawed and washed three times with PBS at 8000g for
442 5 min at 20°C. The pellet was resuspended in 1ml PBS. Serial dilutions (2-fold) of stool
443 microbes in PBS were plated in duplicate in a 96-well flat bottom Corning™ Costar™ 9018
444 plate. Absorbances were read at 570 nm and stool microbes were resuspended to an optical
445 density of 0.05 with 0.1M NaHCO₃, pH 9.4.

446 Serum IgG reactivity to autologous ('self') or heterologous ('non-self', matched
447 patient or control) stool microbes was measured by ELISA. All washes were repeated three
448 times with 200 µl/well PBS and 0.1% Tween™ 20 unless otherwise stated. Nunc
449 MaxiSorp™ flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4°C with
450 100 µl/well of stool microbes. Plates were washed and then blocked for 3h at room
451 temperature under agitation with PBS, 2% BSA fraction V, 1% normal goat serum (Sigma-
452 Aldrich). Plates were incubated for 1 h at 20°C with 50 µl/well of complement inactivated
453 serum samples 2-fold serially diluted (1:80-1:320) in PBS, 2% BSA fraction V, 1% normal
454 goat serum. Plates were washed and incubated for 1h at room temperature under agitation
455 with 100 µl/well of 1:500 goat anti-human IgG H&L (HRP) (Abcam,) diluted in PBS, 2%
456 BSA fraction V, 1% normal goat serum. Plates were washed six times and incubated with

457 TMB high sensitivity substrate solution (BioLegend® UK Ltd) for 5 min at 20°C. The
458 addition of 0.16M H₂SO₄ stopped the reaction and absorbances were read at 450 nm. Results
459 were normalised by subtracting serum only absorbance readings from sample readings.

460 *Microbial flow cytometry*

461 Systemic IgG and faecal IgA binding to stool microbes was assessed by microbial flow
462 cytometry. All buffers were filter sterilised using a 0.22-µm filter before use. Aliquots of
463 non-diluted stool samples were processed and the microbial concentration in each stool
464 sample measured as described earlier. Microbes were resuspended to 2 x 10⁶ cells/ml in PBS
465 with 0.1% BSA. 500µl of complement inactivated serum was diluted 1:100 in PBS with 0.1%
466 BSA and incubated for 30 min at 20°C with 200 µl of 1 x 10⁶ cells/ml of stool microbes. For
467 secretory IgA measurements stool microbes were not incubated with serum. Samples were
468 washed in PBS with 0.1% BSA (5 min, 1.2 x 10⁴ rpm) and microbes were resuspended to 1 x
469 10⁶ cells/ml and incubated with 1:1000 SYBRTM Green I nucleic acid gel stain and 1:100
470 secondary conjugated antibodies (anti-human IgA-APC (Miltenyi Biotec) and anti-human
471 IgG-APC/Cy7 (BioLegend) or their respective isotype controls. Samples were fixed with
472 0.75% v/v paraformaldehyde. Acquisition of cellular events was performed using the BD
473 LSRFortessaTM (BD Biosciences) and analysed using FlowJoTM software. Frequencies of
474 antibody bound stool microbes were expressed as percentages. The percentage of Ig-bound
475 microbes was normalised by subtracting frequency of Ig-bound microbes measured using
476 isotype controls.

477 *Metagenomic shotgun sequencing analysis of total gut microbiota and IgG-coated* 478 *microbes (IgG-Seq)*

479 *Microbial cell sorting*

480 Non-diluted stool samples were processed and stained for IgG flow cytometry analysis as
481 described previously. Isotype controls were not used in microbial cell sorting. Microbes were
482 diluted to 1×10^7 cells/ml and cell sorting achieved using the Sony SH800S cell sorter
483 equipped with four lasers: 488 nm, 405nm, 638nm and 651nm. Prior to sample acquisition
484 the instrument was cleaned and calibrated according to the manufacturer's instructions.
485 Microbes (1×10^6) were collected from the following three fractions: 1) 'all' (SYBR⁺
486 microbes), 2) 'IgG positive' (SYBR⁺IgG⁺), 3) 'IgG negative' (SYBR⁺IgG⁻). Fractions were
487 centrifuged and immediately stored at -20°C as dry pellets.

488 *DNA extraction, processing and sequencing*

489 DNA was extracted using the Gram-positive bacteria genomic DNA purification protocol
490 from the GeneJET DNA genomic DNA purification kit (Thermoscientific) with the following
491 modifications: 1) 0.52 kU/ml achromopeptidase was added to the lysis buffer and the
492 incubation time increased to 60 min; 2) incubation with lysis solution and proteinase K was
493 increased to 50 min. DNA was precipitated using 0.7X solid phase reversible immobilisation
494 bead clean-up with KAPA pure beads (Roche). Whole genome amplification was performed
495 using the REPLI-g advanced DNA single cell kit (QIAGEN). The quality and quantity of
496 amplified genomic DNA were determined using the Agilent Tapestation 4200 and the
497 Quanti-iT™ dsDNA high sensitivity assay kit (Thermo Fisher Scientific). A ready-to-load
498 pooled sequencing library was prepared by the in-house QIB sequencing service using the
499 Illumina DNA prep kit (Illumina, 20018704) and the KAP2G Robust PCR kit (Sigma),
500 followed by sequencing using 2 x 150 bp paired-end chemistry (PE150) on the Illumina
501 NovaSeq 6000 platform (Novogene Ltd., UK).

502 Paired-end sequencing reads were provided as FASTQ format. All raw sequencing
503 reads were pre-processed using tools retrieved from the BioConda repository⁴¹. SeqFu

504 (v1.8.5)⁴² was used to assess the quality of raw sequencing reads and those bases below
505 Phred quality score of 15 were removed using Fastp (v0.20.0)⁴³. Human genomic DNA
506 identified by Kraken2⁴⁴ against the Genome Reference Consortium Human Build 37
507 (GRCh37/hg19) database were removed. Taxonomic assignment of remaining sequencing
508 reads was done using Kraken2⁴⁴ against the ‘PlusPF’ database containing archaea, bacteria,
509 viral, plasma, human1, UniVec_Core, Protozoa and Fungi
510 <https://benlangmead.github.io/aws-indexes/k2>. Abundance of reads at the species level was
511 estimated using Bracken⁴⁵. Taxonomic read counts were converted to relative abundances by
512 total sum scaling to 1.

513 *Relative and quantitative microbiome profiling*

514 The ‘all’ fraction from microbial cell sorting was used for relative microbiome profiling
515 (RMP) and quantitative microbiome profiling (QMP). The cut off threshold of 1×10^{-6} was
516 applied to relative abundances and a pseudocount of 1×10^{-7} was added. The microbial load
517 of each species was calculated on these modified relative abundances using the equation
518 below.

$$absolute\ abundance\ (cells/g)_{ij} = RA_{ij} \times total\ cell\ concentration\ (cells/g)_j$$

519 *Analysing IgG binding of taxa*

520 RMP data was used for IgG binding analysis with a cut off threshold of 1×10^{-5} . In addition,
521 for each participant if a species was not detected in the ‘all’ fraction above the threshold then
522 this species was subsequently removed from respective ‘IgG positive’ and ‘IgG negative’
523 fractions. The ‘IgAScores’ (v.0.1.2)²⁵ R package was used to calculate IgG probability ratios
524 using the ‘igascores’ function with method set to ‘probratio’, pseudocount ‘c’ set to 1×10^{-5}
525 and ‘scaleratio’ set to TRUE.

$$probability\ ratio_{ij} = \log_2 \left(\frac{(IgG_{ij}^+ \times Fraction\ size_j^{IgG^+}) + c}{(IgG_{ij}^- \times Fraction\ size_j^{IgG^-}) + c} \right)$$

526 *Alpha diversity*

527 The diversity function from the ‘vegan’ R package (v.2.5-7)⁴⁶ was used to calculate Shannon
528 indices and inverse Simpson indices. The rarefy function from ‘vegan’ (v.2.5-7)⁴⁶ was used
529 to rarefy reads to the lowest sequencing depth. Observed species’ richness was the number of
530 species remaining following rarefaction.

531 *Beta diversity*

532 The vegdist function from ‘vegan’ (v.2.5-7)⁴⁶ was used to calculate Bray-Curtis indices on
533 relative abundances. The metMDS function from ‘vegan’ (v.2.5-7)⁴⁶ was used to performed
534 non-metric multidimensional scaling (NDMS) on Bray-Curtis indices.

535 *Functional analysis*

536 Gene families were identified using the HMP Unified Metabolic Analysis Network 3.0
537 (HUMANn 3.0) package from the bioBakery suite^{47,48}. In all participants each gene family
538 was filtered by the following criteria: if a gene family was not present in the ‘all’ fraction the
539 reads per kilobase (RPK) were zeroed in the ‘IgG positive’ and ‘IgG negative’ fractions of
540 that participant. The humann_renorm_table utility script from HUMANn 3.0 was used to
541 convert gene families from RPK to relative abundances. Community level classifications of
542 gene families were used in downstream analysis. A cut off threshold of 1×10^{-6} was applied
543 to all samples.

544 To analyse gene families in the microbiome of severe ME/CFS patients compared
545 with household controls the ‘all’ fraction was used. Gene families that were below the
546 threshold in seven or more samples were discarded from downstream analysis. The clr

547 function from the ‘compositions’ R package (v 2.0-4)⁴⁹ was used to CLR transform the
548 relative abundance of gene families. The `pca` function from the ‘mixOmics’ R package (v
549 6.18.1)⁵⁰ was used to perform principal component analysis (PCA) on gene families. Severe
550 ME/CFS patients and their matched household controls were not treated as paired samples in
551 this analysis.

552 To analyse gene families of IgG reactive microbes IgG probability ratios were
553 calculated using the relative abundance of gene families in the ‘IgG positive’ fraction and the
554 ‘IgG negative’ fraction as described earlier, with a pseudocount set to 6×10^{-6} . Gene families
555 that did not have IgG probability ratios in all samples were discarded from downstream
556 analysis. PCA was then performed as described previously.

557 *Statistical analysis*

558 Statistical analyses and graphical representations were performed in R using the following
559 packages: ‘ggplot2’ (v3.4.0)⁵¹, ‘reshape2’ (v1.4.4)⁵², ‘data.table’ (v1.14)⁵³, ‘dplyr’ (v1.1.0)
560 ⁵⁴, ‘ggpubr’ (V0.5.0)⁵⁵. Graphs were also made using GraphPad Prism 5.04. Prior to analysis
561 data were log-transformed if there was evidence for non-normality. Pairwise comparisons
562 between severe ME/CFS patients and their matched household controls were done using a
563 two-tailed paired *t*-test. Correlations were assessed with Pearson (*r*) correlation test.

564 *Common data elements for ME research*

565 This study used the National Institute of Neurological Disorders and Stroke Common Data
566 Elements guidelines’ for reporting microbiome/microorganisms biomarkers in ME/CFS
567 research (<http://www.commondataelements.ninds.nih.gov/>)⁵⁶.

568 **Acknowledgements**

569 We acknowledge East Coast Community Healthcare ME/CFS service and the CFS clinic at
570 Epsom and St Helier University Hospitals NHS Trust for their help recruiting patients, the
571 QIB Human Research Governance Committee (HRGC) for reviewing the HRA application
572 and all the research participants who generously shared their time. KAS was supported by a
573 PhD studentship jointly funded by Invest in ME Research (UK charity number 1153730) and
574 the University of East Anglia. The authors gratefully acknowledge the support of the
575 Biotechnology and Biological Sciences Research Council (BBSRC); The authors gratefully
576 acknowledge the support of the Biotechnology and Biological Sciences Research Council
577 (BBSRC); this research was supported by the BBSRC Institute Strategic Programme Grant
578 Gut Microbes and Health BB/R012490/1 and its constituent projects BBS/E/F/000PR10353
579 and BBS/E/F/000PR10355 (SRC). MD and GS were funded by the BBSRC Core Capability
580 Grant BB/CCG1860/1.

581 **Declaration of interest statement**

582 The authors report there are no competing interests to declare.

583 **Data availability statement**

584 The raw WMS data are available at the European Nucleotide Archive under study accession
585 PRJEB61661. (<http://www.ebi.ac.uk/ena/browser/view/PRJEB61661>).

586 **References**

- 587 1 Lim EJ, Son CG. Review of case definitions for myalgic encephalomyelitis/chronic
588 fatigue syndrome (ME/CFS). *J. Transl. Med.* 2020;18:289. doi: 10.1186/s12967-020-
589 02455-0. PMID: 32727489.
- 590 2 Pendergrast T, Brown A, Sunnquist M, Jantke R, Newton JL, Strand EB, Jason LA.
591 Housebound versus nonhousebound patients with myalgic encephalomyelitis and
592 chronic fatigue syndrome. *Chronic Illn.* 2016;12:292-307. doi:
593 10.1177/1742395316644770. PMID: 27127189.
- 594 3 Chu L, Valencia IJ, Garvert DW, Montoya, JG. Onset Patterns and Course of Myalgic
595 Encephalomyelitis/Chronic Fatigue Syndrome. *Front Pediatr.* 2019;7:12. doi:
596 10.3389/fped.2019.00012. PMID: 30805319.
- 597 4 Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-
598 analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis
599 (CFS/ME). *J. Transl. Med.* 2020;18:100. doi: 10.1186/s12967-020-02269-0. PMID:
600 32093722.
- 601 5 Salari N, Khodayari Y, Hosseini-Far A, Zarei H, Rasoulpoor S, Akbari H,
602 Mohammadi M. Global prevalence of chronic fatigue syndrome among long COVID-
603 19 patients: A systematic review and meta-analysis. *Biopsychosoc. Med.* 2022;16:21.
604 doi: 10.1186/s13030-022-00250-5. PMID: 36274177.
- 605 6 Missailidis D, Annesley SJ, Fisher, PR. Pathological Mechanisms Underlying
606 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Diagnostics (Basel).*
607 2019;9:80. doi: 10.3390/diagnostics9030080. PMID: 31330791.
- 608 7 Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with
609 chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. *Arch.*
610 *Intern. Med.* 2000;160:221-227. doi: 10.1001/archinte.160.2.221. PMID: 10647761.

- 611 8 Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced
612 diversity and altered composition of the gut microbiome in individuals with myalgic
613 encephalomyelitis/chronic fatigue syndrome. *Microbiome*. 2016;4:30. doi:
614 10.1186/s40168-016-0171-4. PMID: 27338587.
- 615 9 Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG,
616 Komaroff AL, Levine S, Montoya JG, et al. Fecal metagenomic profiles in subgroups
617 of patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Microbiome*.
618 2017;5:44. doi: 10.1186/s40168-017-0261-y. PMID: 28441964.
- 619 10 Armstrong CW, McGregor NR, Lewis DP, Butt HL, Gooley PR. The association of
620 fecal microbiota and fecal, blood serum and urine metabolites in myalgic
621 encephalomyelitis/chronic fatigue syndrome. *Metabolomics*. 2016;13:8. doi:
622 10.1007/s11306-016-1145-z.
- 623 11 Xiong R, Gunter C, Fleming E, Vernon SD, Bateman L, Unutma. Multi-'omics of gut
624 microbiome-host interactions in short- and long-term myalgic
625 encephalomyelitis/chronic fatigue syndrome patients. *Cell Host Microbe*.
626 2023;31:273-287.e275. doi: 10.1016/j.chom.2023.01.001. PMID: 36758521.
- 627 12 Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, Cheng A, March D,
628 Hornig M, Komaroff AL et al. Deficient butyrate-producing capacity in the gut
629 microbiome is associated with bacterial network disturbances and fatigue symptoms
630 in ME/CFS. *Cell Host Microbe*. 2023;31:288-304.e288. doi:
631 10.1016/j.chom.2023.01.004. PMID: 36758522.
- 632 13 Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of
633 enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of
634 gram-negative enterobacteria in the etiology of CFS and for the presence of an

- 635 increased gut-intestinal permeability. *J. Affect. Disord.* 2007;99:237-240. doi:
636 10.1016/j.jad.2006.08.021. PMID: 17007934.
- 637 14 Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D, Robertson CE,
638 Schrodi SJ, Yale S, Frank DN. Changes in Gut and Plasma Microbiome following
639 Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
640 (ME/CFS). *PLoS One.* 2015;10:e0145453. doi: 10.1371/journal.pone.0145453.
641 PMID: 26683192.
- 642 15 Duchmann R, Neurath MF, Meyer zum Büschenfelde KH. Responses to self and non-
643 self intestinal microflora in health and inflammatory bowel disease. *Res. Immunol.*
644 1997;148:589-594. doi: 10.1016/s0923-2494(98)80154-5. PMID: 9588839.
- 645 16 Harmsen HJ, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn's disease patients
646 have more IgG-binding fecal bacteria than controls. *Clin. Vaccine Immunol.*
647 2012;19:515-521. doi:10.1128/cvi.05517-11. PMID: 22336288.
- 648 17 Ruff WE, Greiling TM, Kriegel MA. Host-microbiota interactions in immune-
649 mediated diseases. *Nat. Rev. Microbiol.* 2020;18:521-538. doi: 10.1038/s41579-020-
650 0367-2. PMID: 32457482.
- 651 18 Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M. In
652 myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity
653 against 5-HT is associated with immuno-inflammatory pathways and bacterial
654 translocation. *J. Affect. Disord.* 2013;150:223-230. doi: 10.1016/j.jad.2013.03.029.
655 PMID: 23664637.
- 656 19 Quigley EMM. Gut bacteria in health and disease. *Gastroenterol Hepatol (N Y).*
657 2013;9:560-569. PMID: 24729765.

- 658 20 Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and
659 Therapeutic Use of IgM Antibodies. *Antibodies (Basel)*. 2020;9:53. doi:
660 10.3390/antib9040053. PMID: 33066119.
- 661 21 de Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability.
662 *Antibodies (Basel)*. 2019;8:57. doi: 10.3390/antib8040057. PMID: 31817406.
- 663 22 Vogl T, Kalka IN, Klompus S, Leviatan S, Weinberger A, Segal E. Systemic antibody
664 responses against human microbiota flagellins are overrepresented in chronic fatigue
665 syndrome patients. *Sci Adv*. 2022;8:eabq2422. doi: 10.1126/sciadv.abq2422. PMID:
666 36149952.
- 667 23 Vogl T, Klompus S, Leviatan S, Kalka IN, Weinberger A, Wijmenga C, Fu J,
668 Zhernakova A, Weersma RK, Segal E. Population-wide diversity and stability of
669 serum antibody epitope repertoires against human microbiota. *Nat. Med*.
670 2021;27:1442-1450. doi: 10.1038/s41591-021-01409-3. PMID: 34282338.
- 671 24 Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, Degan PH,
672 Hu J, Peter I, Zhang W, et al. Immunoglobulin A coating identifies colitogenic
673 bacteria in inflammatory bowel disease. *Cell*. 2014;158:1000-1010. doi:
674 10.1016/j.cell.2014.08.006. PMID: 25171403.
- 675 25 Jackson MA, Pearson C, Ilott NE, Huus KE, Hegazy AN, Webber J, Finlay BB,
676 Macpherson AJ, Powrie F, Lam LH. Accurate identification and quantification of
677 commensal microbiota bound by host immunoglobulins. *Microbiome*. 2021;9:33.
678 doi: 10.1186/s40168-020-00992-w. PMID: 33516266.
- 679 26 Redondo-Useros N, Nova E, González-Zancada N, Díaz LE, Gómez-Martínez S,
680 Marcos A. Microbiota and Lifestyle: A Special Focus on Diet. *Nutrients*.
681 2020;12:1776. doi: 10.3390/nu12061776. PMID: 32549225.

- 682 27 Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, Andreu-
683 Sánchez S, Chen L, Collij V, Hu S et al. Environmental factors shaping the gut
684 microbiome in a Dutch population. *Nature*. 2022;604:732-739. doi:10.1038/s41586-
685 022-04567-7. PMID: 35418674.
- 686 28 Lupo GFD, Rocchetti G, Lucini L, Lorusso L, Manara E, Bertelli M, Puglisi E,
687 Capelli E. Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic
688 Encephalomyelitis (CFS/ME). *Sci. Rep.* 2021;11:7043. doi: 10.1038/s41598-021-
689 86425-6. PMID: 33782445.
- 690 29 Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol.*
691 2016;16:626-638. doi:10.1038/nri.2016.90. PMID: 27546235.
- 692 30 Milan-Mattos JC, Anibal FF, Perseguini NM, Minatel V, Rehder-Santos P, Castro
693 CA, Vasilceac FA, Mattiello SM, Faccioli LH, Catai AM. Effects of natural aging and
694 gender on pro-inflammatory markers. *Braz J Med Biol Res.* 2019;52:e8392. doi:
695 10.1590/1414-431x20198392. PMID: 31411315.
- 696 31 Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables
697 confound gut microbiota studies of human disease. *Nature*. 2020;587:448-454. doi:
698 10.1038/s41586-020-2881-9. PMID: 33149306.
- 699 32 Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, Gibbons
700 SM, Larsen P, Shogan BD, Weiss S, et al. Longitudinal analysis of microbial
701 interaction between humans and the indoor environment. *Science*. 2014;345:1048-
702 1052. doi: 10.1126/science.1254529. PMID: 25170151.
- 703 33 Guenther S, Loebel M, Mooslechner AA, Knops M, Hanitsch LG, Grabowski P,
704 Wittke K, Meisel C, Unterwalder N, Volk HD, et al. Frequent IgG subclass and
705 mannose binding lectin deficiency in patients with chronic fatigue syndrome. *Hum.*
706 *Immunol.* 2015;76:729-735. doi: 10.1016/j.humimm.2015.09.028. PMID: 26429318.

- 707 34 Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME,
708 Zareian N, Accardi G. Immunosenescence and Its Hallmarks: How to Oppose Aging
709 Strategically? A Review of Potential Options for Therapeutic Intervention. *Front.*
710 *Immunol.* 2019;10:2247. doi: 10.3389/fimmu.2019.02247. PMID: 31608061.
- 711 35 Eaton-Fitch N, du Preez S, Cabanas H, Staines D, Marshall-Gradisnik S. A systematic
712 review of natural killer cells profile and cytotoxic function in myalgic
713 encephalomyelitis/chronic fatigue syndrome. *Syst Rev.* 2019;8:279.
714 doi:10.1186/s13643-019-1202-6. PMID: 31727160.
- 715 36 Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, Baxter A, Nathan
716 N, Anderson W, Gordon E. Metabolic features of chronic fatigue syndrome. *Proc.*
717 *Natl. Acad. Sci. U. S. A.* 2016;113:E5472-5480. doi: 10.1073/pnas.1607571113.
718 PMID: 27573827.
- 719 37 Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue
720 syndrome: how could the illness develop? *Metab. Brain Dis.* 2019;34:385-415. doi:
721 10.1007/s11011-019-0388-6. PMID: 30758706.
- 722 38 Baker R, Shaw EJ. Diagnosis and management of chronic fatigue syndrome or
723 myalgic encephalomyelitis (or encephalopathy): summary of NICE guidance. *BMJ.*
724 2007;335:446-448. doi: 10.1136/bmj.39302.509005.AE. PMID: 17762037.
- 725 39 Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic
726 fatigue syndrome: a comprehensive approach to its definition and study. *International*
727 *Chronic Fatigue Syndrome Study Group. Ann Intern Med.* 1994;121:953-9. doi:
728 10.7326/0003-4819-121-12-199412150-00009. PMID: 7978722.
- 729 40 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time.
730 *Scand J Gastroenterol.* 1997;32:920-4. doi: 10.3109/00365529709011203. PMID:
731 9299672.

- 732 41 Gruning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH, Valieris R,
733 Köster J; Bioconda Team. Bioconda: sustainable and comprehensive software
734 distribution for the life sciences. *Nat Methods*. 2018;15:475-476. doi:
735 10.1038/s41592-018-0046-7. PMID: 29967506.
- 736 42 Telatin A, Fariselli P, Birolo G. SeqFu: A Suite of Utilities for the Robust and
737 Reproducible Manipulation of Sequence Files. *Bioengineering (Basel)*. 2021;8:59.
738 doi: 10.3390/bioengineering8050059. PMID: 34066939.
- 739 43 Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
740 *Bioinformatics*. 2018;34:i884-i890. doi: 10.1093/bioinformatics/bty560. PMID:
741 30423086.
- 742 44 Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.
743 *Genome Biol*. 2019;20:257. doi: 10.1186/s13059-019-1891-0. PMID: 31779668.
- 744 45 Lu J, Breitwieser FP, Thielen P, Salzberg SL. Bracken: estimating species abundance
745 in metagenomics data. *PeerJ Computer Science*. 2017;3:e104. doi: 10.7717/peerj-
746 cs.104
- 747 46 Oksanen J, Simpson GL, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara
748 RB, Solymos P, Stevens MHH, Szoecs E, et al. `_vegan: Community Ecology`
749 `Package_`. R package version v.2.6-4. 2022. <[https://CRAN.R-](https://CRAN.R-project.org/package=vegan)
750 [project.org/package=vegan](https://CRAN.R-project.org/package=vegan)>.
- 751 47 Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan
752 A, Manghi P, Scholz M, Thomas AM, et al. Integrating taxonomic, functional, and
753 strain-level profiling of diverse microbial communities with bioBakery 3. *Elife*.
754 2021;10:e65088. doi: 10.7554/eLife.65088. PMID: 33944776.

- 755 48 McIver LJ, Abu-Ali G, Franzosa EA, Schwager R, Morgan XC, Waldron L, Segata N,
756 Huttenhower C. bioBakery: a meta'omic analysis environment. *Bioinformatics*.
757 2018;34:1235-1237. doi: 10.1093/bioinformatics/btx754. PMID: 29194469.
- 758 49 van den Boogaart KG, Tolosana-Delgado R, Bren M. `_compositions`: Compositional
759 Data Analysis_. R package version 2.0-6. 2023. <[https://CRAN.R-
760 project.org/package=compositions](https://CRAN.R-project.org/package=compositions)>.
- 761 50 Rohart F, Gautier B, Singh A, Lê Cao KA. `mixOmics`: An R package for 'omics
762 feature selection and multiple data integration. *PLoS Comput Biol*.
763 2017;13:e1005752. doi: 10.1371/journal.pcbi.1005752. PMID: 29099853.
- 764 51 Wickham, H. `ggplot2`: Elegant Graphics for Data Analysis. New York: Springer-
765 Verlag; 2016.
- 766 52 Wickham, H. Reshaping Data with the `reshape` Package. *J Stat Soft*. 2007;21:1-20.
767 doi: 10.18637/jss.v021.i12.
- 768 53 Dowle M, Srinivasan A. `_data.table`: Extension of `data.frame`_. R package version
769 1.14.6. 2022. <<https://CRAN.R-project.org/package=data.table>>.
- 770 54 Wickham H, François R, Henry L, Müller K, Vaughan D. `_dplyr`: A Grammar of Data
771 Manipulation_. R package version 1.1.0. 2023. <[https://CRAN.R-
772 project.org/package=dplyr](https://CRAN.R-project.org/package=dplyr)>.
- 773 55 Alboukadel K. `_ggpubr`: 'ggplot2' Based Publication Ready Plots_. R package version
774 0.6.0. 2023. <<https://CRAN.R-project.org/package=ggpubr>>.
- 775 56 Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National
776 Institute of Neurological Disorders and Stroke Common Data Element Project -
777 approach and methods. *Clin Trials*. 2012;9:322-329. doi:
778 10.1177/1740774512438980. PMID: 22371630.

779

780 Table 1. Severe ME/CFS clinical characteristics

	Participants affected (%)	Mean (SD)	Range
Age of ME/CFS onset (years)	-	25.0 (9.34)	12-38
Length of ME/CFS (years)	-	8.4 (6.83)	2-21
Symptoms			
Post exertional malaise	100	-	-
Non-restorative sleep	100	-	-
Headaches of a new onset, pattern and severity	80	-	-
Recurrent sore throat with enlarged glands in neck	40	-	-
Impaired concentration	100	-	-
Impaired memory	80	-	-
Joint pain	60	-	-
Muscle pain	80	-	-
Visual and/or auditory hypersensitivity	100	-	-
Irritable bowel syndrome	100	-	-
Questionnaire (maximum score)			
Shortened SF-36 (30) *	-	11.0 (1.73)	10-14
Chalder fatigue – physical (28) *	-	24.0 (3.67)	18-27
Chalder fatigue – mental (16) *	-	13.5 (1.12)	12-15
HADS – anxiety (21) *	-	7.8 (4.55)	3-15
HADS – depression (21) *	-	6.5 (5.50)	3-16

Self efficacy (60) **	-	12.0 (7.35)	3-21
Visual analogue (100) *	-	62.5 (36.31)	0-90
Epworth sleepiness (24) ***	-	7.5 (14)	1-14

* questionnaire completed by 4 patients

** questionnaire completed by 3 patients

*** questionnaire completed by 2 patients

781

782

783 Table 2. Proportion of species detected that are recognised by serum IgG

Pair	Participant	Number of species detected per fraction			Proportion of species IgG+
		Only IgG-	Only IgG+	Both IgG- and IgG+	
1	Patient	7	7	201	0.967
	Control	23	7	173	0.887
2	Patient	18	7	190	0.916
	Control	21	6	202	0.908
3	Patient	107	4	154	0.596
	Control	14	12	145	0.918
4	Patient	4	19	138	0.975
	Control	29	6	168	0.857
5	Patient	9	18	162	0.952
	Control	15	31	206	0.940

784

785

786 SUPPLEMENTARY TABLE 1. The size of IgG positive and IgG negative fractions
787 collected during IgG-Seq. This data was used to calculation of IgG probability ratio scores.

Pair	Participant	Fraction sizes (%)	
		IgG+	IgG-
1	Patient	21.1	79.5
	Control	18.0	79.8
2	Patient	35.1	58.1
	Control	48.1	49.7
3	Patient	17.9	65.5
	Control	46.3	44.9
4	Patient	65.0	29.0
	Control	33.7	63.1
5	Patient	24.2	75.3
	Control	62.7	31.1

788

789

790 FIGURE 1. Stool consistency. (A) Analysis of stool consistency using the Bristol stool form
791 scale (BSFS) in severe ME/CFS patients (n=5) and matched household controls (n=5). P
792 values were calculated using a two-tailed paired t-test. (B) Water content in stool samples in
793 severe ME/CFS patients (n=5) and matched household controls (n=5). P values were
794 calculated using a two-tailed paired t-test.

795

796 FIGURE 2. Concentration of IgA measured by ELISA in the stool of severe ME/CFS patients
797 (n=5) and matched household controls (n=5) for (A) microbe bound IgA, and (B) microbe
798 non-bound IgA. For both plots *p values* were calculated using a two-tailed paired *t*-test.

799

800 FIGURE 3. Profiling stool IgA. (A) Overview of sample preparation for IgA-bound microbe
801 fluorescent activated cell sorting (FACS) analysis. (B) Representative flow cytometric
802 analysis of IgA-bound stool microbes. (C) Proportion of stool microbes bound by IgA in
803 severe ME/CFS patients (n=5) and matched household controls (n=5). P values were
804 calculated using a two-tailed paired t-test. (D) Analysis of IgA-bound microbial load in
805 severe ME/CFS patients (n=5) and matched household controls (n=5). P values were
806 calculated using a two-tailed paired t-test.

807

808 FIGURE 4. Serum IgG reactivity to autologous and heterologous stool microbes. (A)
809 Overview of assessment of IgG responses to indigenous (autologous) and foreign
810 (heterologous) stool microbes in severe ME/CFS patients and matched healthy household
811 controls. (B) Level of IgG in serum of severe ME/CFS patients (n=5) and household control
812 (n=5) binding to stool microbes from patient and control stool samples in vitro. (C) Levels of

813 IgG in serum of severe ME/CFS patients (n=5) and their matched household controls
814 quantified by ELISA (n=5). Two-tailed paired t-tests were used to calculate P values.

815

816 FIGURE 5. Quantifying stool microbes recognised by autologous serum IgG. (A) Overview
817 of sample preparation for IgG-bound microbe FACS analysis. (B) Representative analysis of
818 serum IgG binding to stool microbes. (C) Analysis of the proportion of stool microbes bound
819 by serum IgG in severe ME/CFS patients (n=5) and matched household controls (n=5). P
820 values were calculated using a two-tailed paired t-test.

821

822 FIGURE 6. IgG-Seq. (A) IgG-Seq protocol used to determine taxa from stool samples
823 reactive to autologous serum IgG. (B) Representative flow cytometric dot plot showing IgG-
824 Seq gating strategy based upon forward scatter (FSC) and back scatter (BSC) characteristics,
825 followed by discrimination of singlets from doublets. SYBR+ microbes were discriminated
826 from auto fluorescent debris and collected for profiling of all stool microbes. IgG positive
827 and IgG negative populations were sorted from SYBR+ events. (C) Pairwise comparisons of
828 observed richness of IgG positive and IgG negative microbes in severe ME/CFS patients
829 (n=5) and matched household controls (n=5). Analyses were performed at the species-level
830 reads rarefied to the lowest sequencing depth. P values were measured using two-tailed
831 paired t-tests. (D) Beta diversity of IgG positive species (filled shapes) and IgG negative
832 species (unfilled shapes) in severe ME/CFS patients (circles) and household controls
833 (squares). Beta-diversity was calculated using Bray-Curtis dissimilarity, presented on a non-
834 metric multi-dimensional scaling (NMDS) plot.

835

836 FIGURE 7. Probability of serum IgG binding to autologous stool microbes from severe
837 ME/CFS patients (n=5) and matched household controls (n=5). IgG probability ratios for
838 species detected in all participants stool samples.

839

840 SUPPLEMENTARY FIGURE 1. Study participant recruitment pathway. Severe ME patients
841 were recruited from the CFS clinic at Epsom and St Helier University Hospitals (ESTH),
842 Carshalton, UK and the ME/CFS service at East Coast Community Healthcare Centre,
843 Lowestoft, UK.

844

845 SUPPLEMENTARY FIGURE 2. Stool microbial load. Flow cytometric analysis of SYBR
846 Green+ microbial load in stool samples of severe ME/CFS patients (n=5) and matched
847 household controls (n=5).

848

849 SUPPLEMENTARY FIGURE 3. Stool microbiome profiling of severe ME/CFS patients
850 (n=5) and matched household controls (n=5). (A) Relative microbiome profiling (RMP) at
851 the genus-level. (B) quantitative microbiome profiling (QMP, cells per gram of faeces) at the
852 genus-level. (C) RMP at the species-level. (D) QMP at the species-level.

853

854 SUPPLEMENTARY FIGURE 4. Pairwise alpha- and beta-diversity comparisons of the stool
855 microbiomes of severe ME/CFS patients (n=5) and matched household controls (n=5).
856 Analyses were performed at the species-level on shotgun metagenomics data from SYBR+
857 stool microbes. (A) Alpha diversity measures of Shannon index, inverse Simpson index and
858 richness based on reads rarefied to the lowest sequencing depth. P values were measured



859 using two-tailed paired t-tests. (B) Beta diversity of relative microbiome profiling (RMP) and
860 quantitative microbiome profiling (QMP, cells per gram faeces). Beta-diversity was
861 calculated using Bray-Curtis dissimilarity, presented on a non-metric multi-dimensional
862 scaling (NMDS) plot.

863

864 SUPPLEMENTARY FIGURE 5. Functional composition of stool metagenomes from severe
865 ME/CFS patients (circles) (n=5) and matched household controls (squares) (n=5). Principal
866 component analysis (PCA) of the relative abundances of gene families. Pair numbers are
867 depicted on the graph but were not used in analysis.

868

869 SUPPLEMENTARY FIGURE 6. Functional profiling of stool microbes reactive with serum
870 IgG. Principal component analysis (PCA) of IgG probability ratios of gene families from the
871 stool microbiome in severe ME/CFS patients (circles) (n=5) and matched household controls
872 (squares) (n=5). Pair numbers are depicted on the graphs but were not used in analysis.



A**B****Disease status:**

Patient ●

Control ■

Pair:

1 ▲ 2 ▲ 3 ▲ 4 ▲ 5 ▲

A**B****Disease status:**

Patient ●

Control ■

Pair:










1 ▲




2 ▲

3 ▲


4 ▲

5 ▲









A



B



C




Disease status:

Patient ●
Control ■

Pair:

1 ▲ 2 ▲ 3 ▲ 4 ▲ 5 ▲

Singlets



Singlets

